TNF inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.
Preliminary findings from two studies point to low overall rates of breakthrough COVID-19 following vaccination in people with rheumatic and musculoskeletal diseases.
Most people with inflammatory diseases treated with immunomodulatory therapies mount an antibody response to mRNA vaccines against SARS-CoV-2, but the response may be blunted in those taking glucocorticoids or B cell-depleting therapies, shows the COVaRiPAD study.
